Background Endothelial function is a marker for cardiovascular risk. Thus, abnormal endothelial function may be associated with adverse 1-year outcome in patients presenting to the emergency department chest pain unit (CPU). Methods Following endothelial function testing, using EndoPAT 2000 in 300 consecutive subjects with chest pain and no history of coronary artery disease (CAD) presenting to CPU, patients underwent coronary computerized tomographic angiography (CCTA) or single-photon emission computed tomography according to availability. Results Mean 10-year Framingham risk score (FRS) was 6.6 ± 5.9%, median reactive hyperemia index (RHI) as a measure of endothelial function 2.08 and mean was 2.0 ± 0.4. During a 1-year follow-up, the 20 (6.6%) patients who developed major adverse cardiovascular end-points (MACE), including all-cause mortality, non-fatal myocardial infarction, hospitalization for heart failure or angina pectoris, stroke, coronary artery bypass grafting and percutaneous coronary interventions, had higher 10-year FRS (10.5 ± 8.2% vs 6.3 ± 5.7%; p < 0.001), lower baseline RHI (1.43 ± 0.41 vs 2.10 ± 0.44; p < 0.001) and a greater extent of coronary atherosclerosis lesions (70% vs 3.9%, p < 0.001) in the CPU CCTA, compared to those without MACE. RHI ≤ the median was associated with higher 1-year MACE (13% vs 0.7%, p < 0.001) compared to RHI > the median. Multivariate analysis demonstrated that RHI ≤ the median is an independent predictor of coronary atherosclerosis lesions in the CPU CCTA (OR 5.98, 95% CI 03.29-10.88; p < 0.001) and 1-year MACE (OR 15.207, 95% CI 2.00-115.33; p < 0.01). Conclusions Our findings suggest that non-invasive endothelial function testing may have clinical utility in triaging patients in the CPU and in predicting 1-year MACE.
- Coronary artery disease
- Endothelial function
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine